Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.53 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.43 |
| ▸ | TLR2 | O60603 | 2/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 5/20 | 0.40 |
| ▸ | RRM1 | P23921 | 1/20 | 0.40 |
| ▸ | GLP1R | P43220 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13657783 | 0.92 | DPP7 (0.50) | SIRT6SIRT1DPP7GNAI3GNAO1 | |
| SCHEMBL13630642 | 0.89 | SIRT6 (0.56) | SIRT6SIRT1DPP7TLR2GNAI3 | |
| SCHEMBL13630636 | 0.89 | SIRT6 (0.53) | SIRT6SIRT1DPP7TLR2GNAI3 | |
| SCHEMBL19788546 | 0.82 | SIRT1 (0.65) | SIRT6SIRT1DPP7TLR2GNAI3 | |
| SCHEMBL26805124 | 0.81 | SIRT6 (0.48) | SIRT6SIRT1DPP7TLR2GNAI3 | |
| SCHEMBL12797998 | 0.81 | SIRT6 (0.51) | SIRT6SIRT1DPP7TLR2GNAI3 | |
| SCHEMBL12797999 | 0.81 | SIRT6 (0.51) | SIRT6SIRT1DPP7TLR2GNAI3 | |
| SCHEMBL9885171 | 0.81 | NAAA (0.51) | SIRT6SIRT1TLR2 | |
| SCHEMBL28052076 | 0.81 | GNAI3 (0.58) | SIRT6SIRT1DPP7GNAI3GNAO1 | |
| SCHEMBL28052266 | 0.81 | GNAI3 (0.58) | SIRT6SIRT1DPP7GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324146-A1 | Dendrimeric Enzyme Inhibitors | STARPHARMA PTY LTD (AU) | 2010-12-23 | — | — | US | disclosed |
| US-20090269298-A1 | AGENT FOR THE PREVENTION AND TREATMENT OF SEXUALLY TRANSMITTED DISEASES-I | STARPHARMA PTY LTD. | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090269298-A1 | AGENT FOR THE PREVENTION AND TREATMENT OF SEXUALLY TRANSMITTED DISEASES-I | DNPEP, CTSA, TLR1 | SIRT6 607/4885SIRT1 441/4885DPP7 368/4885 |
| US-20100324146-A1 | Dendrimeric Enzyme Inhibitors | CD44, GAA, HPSE | SIRT6 829/4885SIRT1 998/4885DPP7 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.